Mayo Clinic Feb 15, 2022 Mayo Clinic Exploring PDS Biotech's PDS0101, Merck's Keytruda in HPV-Associated Oropharyngeal Cancer Oct 13, 2021 Mayo Clinic, Personalis Ink Comprehensive Genomics Research Collaboration May 21, 2021 In Brief This Week: Mayo Clinic, Real-World Evidence Alliance, Burning Rock Biotech Feb 19, 2021 BRCA2 Variants of Unknown Significance Reclassified Through Functional Data Additions Feb 18, 2021 Stella Diagnostics, Mayo Clinic Collaborating on Barrett's Esophagus Protein Markers Jan 21, 2021 Breast Cancer Risk Gene Associations Refined in Large-Scale Studies Oct 30, 2020 Broad Genetic Testing Uncovers Additional Risk Variants in Cancer Patients, Study Finds Sep 15, 2020 Pancreatic Cancer Treatment Clues Uncovered From Genomic, Chromatin Profiles Jan 8, 2020 Personal Genome Diagnostics, Mayo Clinic to Collaborate on Cancer Genomic Tests Dec 20, 2019 Telo Genomics, Mayo Clinic Collaborate on Multiple Myeloma Clinical Studies Dec 18, 2019 Ambry Genetics, Mayo Clinic Develop Mutation Prevalence Tool to Guide Docs on Appropriate Testing Premium Oct 30, 2019 Exact Sciences Preparing to Launch Improved Cologuard, Liver Cancer Test Premium Oct 14, 2019 Exact Sciences, Mayo Clinic Launch Real-World Impact Study for Cologuard Jun 5, 2019 Diagnostic Power of Pancreatic Cancer Blood Test Gets a Boost From Methylated DNA Markers Premium Jun 4, 2019 Color Panel Reveals Hereditary Cancer Risk in Trinidad and Tobago Breast Cancer Patients Premium Aug 7, 2018 Triple-Negative Breast Cancer Risk Linked to Germline Variants in Several Cancer Genes May 11, 2017 Which PD-L1 Assay to Use With Which NSCLC Immunotherapy? There's an Atlas for That Now Premium Breaking News Dragonfly Therapeutics Begins Phase II Trial of HER2-Targeted NK-Cell Engager Touchlight to Provide DNA Vector for Odimma Therapeutics' Personalized Neoantigen Vaccine Trial FDA Approves Thermo Fisher HLA Typing Test as CDx for Immunocore Uveal Melanoma Therapy Caris Life Sciences, Hummingbird Bioscience Partner on Anti-HER3 Therapy Advancement Akeso, Summit Therapeutics Ink $5B Licensing Deal for PD-1/VEGF Bispecific Antibody Bluestar Genomics to Study Pancreatic Cancer Early Detection Test in Type 2 Diabetes Patients
